Emavusertib hydrochloride, identified by its CAS number 2376399-42-5, is a small molecule inhibitor that targets specific pathways involved in cancer cell proliferation and survival. It is primarily studied for its potential therapeutic applications in oncology, particularly in the treatment of hematological malignancies. The compound exhibits selective inhibition of certain kinases, which play crucial roles in signal transduction and cellular processes. Emavusertib hydrochloride is characterized by its solubility in aqueous solutions, which facilitates its administration in clinical settings. Its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion, are critical for determining its efficacy and safety profile. As with many investigational drugs, ongoing research is focused on understanding its mechanism of action, optimal dosing regimens, and potential side effects. Overall, Emavusertib hydrochloride represents a promising avenue in targeted cancer therapy, with the aim of improving patient outcomes through precision medicine approaches.

Emavusertib hydrochloride

2376399-42-5: Emavusertib hydrochloride, identified by its CAS number 2376399-42-5, is a small molecule inhibitor that targets specific pathways involved in cancer cell proliferation and survival. It is primarily studied for its potential therapeutic applications in oncology, particularly in the treatment of hematological malignancies. The compound exhibits selective inhibition of certain kinases, which play crucial roles in signal transduction and cellular processes. Emavusertib hydrochloride is characterized by its solubility in aqueous solutions, which facilitates its administration in clinical settings. Its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion, are critical for determining its efficacy and safety profile. As with many investigational drugs, ongoing research is focused on understanding its mechanism of action, optimal dosing regimens, and potential side effects. Overall, Emavusertib hydrochloride represents a promising avenue in targeted cancer therapy, with the aim of improving patient outcomes through precision medicine approaches.

<p>Emavusertib (CA-4948) hydrochloride, a selective and potent IRAK4/FLT3 inhibitor, is designed for oral administration. It achieves an IC 50 of 57 nM against IRAK4 in a FRET kinase assay and demonstrates anti-tumor activity [1] [2] [3].</p>

CAS 2376399-42-5

Emavusertib hydrochloride

Emavusertib hydrochloride

Ref: TM-T86366